Overview

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

Status:
Active, not recruiting

Trial end date:
2021-11-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv mecarbil or placebo

Phase:

Phase 3

Details

Lead Sponsor:

Amgen
Cytokinetics

Collaborators:

Cytokinetics
Servier